Towa Pharmaceutical Co., Ltd. (TYO:4553)

Market Cap	173.28B +17.9%
Revenue (ttm)	279.94B +6.8%
Net Income	8.27B -48.3%
EPS	167.95 -48.3%
Shares Out	49.23M
PE Ratio	20.96
Forward PE	7.50
Dividend	85.00 (2.33%)
Ex-Dividend Date	Sep 29, 2026

Volume	106,400
Open	3,470.00
Previous Close	3,520.00
Day's Range	3,440.00 - 3,550.00
52-Week Range	2,764.00 - 4,490.00
Beta	-0.09
Analysts	Buy
Price Target	5,250.00 (+47.89%)
Earnings Date	Nov 11, 2026

About Towa Pharmaceutical

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. The company operates through two segments; Domestic and Overseas. It provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from tablets, capsules, injectable, patches, eye drops, and other products. The company also offers IT service related to healthcare; disease risk testing services; and sale of...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1951
• Employees: 4,923
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4553

Financial Performance

In fiscal year 2026, Towa Pharmaceutical's revenue was 273.71 billion, an increase of 5.44% compared to the previous year's 259.59 billion. Earnings were 5.25 billion, a decrease of -72.35%.

Analyst Summary

According to 6 analysts, the average rating for 4553 stock is "Buy." The 12-month stock price target is ¥5,250, which is an increase of 47.89% from the latest price.

Price Target

¥5,250

(47.89% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 14, 2026

Data Sources Report a data error